Table 1.
Baseline Characteristics of 17,487 Patients Who Initiated Antiviral Treatment in the Veterans Affairs Nationally From January 2014 to June 2015
| Genotype 1, %b
|
Genotype 2, %, b
|
Genotype 3, %b
|
Genotype 4, %b
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | All patients, n (%)a | LDV/SOF | LDV/SOF+RIBA | PrOD | PrOD+RIBA | SOF+RIBA | LDV/SOF+RIBA | SOF+PEG+RIBA | SOF+RIBA | LDV/SOF±RIBA | PrOD±RIBA |
| All patients | 17,487 (100) | 8140 | 2692 | 776 | 2366 | 2131 | 392 | 140 | 715 | 103 | 32 |
| Age, y, mean (SD) | 61 (7) | 61 (6) | 62 (5) | 62 (6) | 61 (6) | 61 (7) | 58 (8) | 58 (5) | 58 (8) | 60 (7) | 60 (8) |
| Male | 16,920 (97) | 96 | 97 | 97 | 98 | 97 | 98 | 97 | 98 | 94 | 100 |
| Race/ethnicity | |||||||||||
| White, non-Hispanic | 9141 (52) | 46 | 52 | 40 | 48 | 70 | 74 | 68 | 77 | 58 | 48 |
| Black, non-Hispanic | 5043 (29) | 36 | 27 | 45 | 32 | 8.9 | 2.0 | 6.1 | 3.4 | 32 | 39 |
| Hispanic | 913 (5.3) | 4.3 | 6.8 | 3.0 | 5.6 | 6.1 | 7.8 | 8.2 | 7.3 | 6.6 | 0 |
| Asian, Pacific Islander, American Indian | 280 (1.6) | 1.4 | 1.6 | 0.6 | 2.0 | 1.6 | 3.2 | 2.7 | 2.7 | 0 | 3.0 |
| Declined to answer, missing | 2110 (12) | 12 | 13 | 11 | 13 | 13 | 13 | 15 | 9.8 | 2.8 | 9.0 |
| Treatment experienced | 5109 (29) | 25 | 56 | 21 | 26 | 23 | 26 | 48 | 31 | 26 | 24 |
| Prior interferon | 4680 (27) | 22 | 51 | 20 | 24 | 21 | 23 | 48 | 28 | 24 | 24 |
| Prior boceprevir | 929 (5.3) | 5.4 | 17 | 0.9 | 1.6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prior telaprevir | 225 (1.3) | 1.3 | 4.5 | 0.1 | 0.04 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prior simeprevir+SOF | 306 (1.8) | 1.5 | 6.5 | 0.6 | 0.9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prior SOF | 741 (4.2) | 2.9 | 14 | 1.2 | 2.2 | 2.6 | 5.4 | 2.7 | 2.6 | 3.8 | 0 |
| Prior LDV/SOF | 142 (0.8) | 1.2 | 1.2 | 0.6 | 0.4 | 0 | 0.5 | 0 | 0.5 | 0.9 | 0 |
| Prior PrOD | 68 (0.4) | 0.2 | 0.4 | 0.6 | 1.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| HCV RNA viral load >6 million IU/mL | 3248 (19) | 17 | 16 | 22 | 23 | 24 | 15 | 15 | 15 | 14 | 6 |
| HIV co-infection | 713 (4.1) | 6.0 | 3.7 | 2.1 | 1.4 | 2.4 | 2.0 | 4.1 | 1.8 | 8.5 | 3.0 |
| Cirrhosis | 5250 (30) | 23 | 58 | 6.8 | 29 | 25 | 35 | 54 | 43 | 25 | 25 |
| Decompensated cirrhosis | 1448 (8.3) | 5.9 | 18 | 0.9 | 4.5 | 7.9 | 13 | 11 | 16 | 7.8 | 9.4 |
| Hepatocellular carcinoma | 482 (2.8) | 2.1 | 6.1 | 0.6 | 2.0 | 1.6 | 4.9 | 4.3 | 4.3 | 1.9 | 3.1 |
| Liver transplantation | 391 (2.2) | 1.7 | 7.5 | 0.1 | 0.2 | 1.5 | 3.2 | 0.7 | 3.2 | 1.9 | 0 |
| Diabetes | 5106 (29) | 30 | 38 | 29 | 25 | 27 | 25 | 20 | 25 | 27 | 18 |
| Alcohol use disorder | 7720 (44) | 44 | 45 | 38 | 40 | 45 | 53 | 50 | 51 | 37 | 42 |
| Substance use disorder | 6466 (37) | 39 | 33 | 33 | 34 | 35 | 43 | 40 | 43 | 41 | 36 |
| Depression | 8284 (47) | 49 | 51 | 41 | 43 | 45 | 49 | 51 | 51 | 52 | 48 |
| PTSD | 4689 (27) | 28 | 27 | 23 | 25 | 26 | 26 | 18 | 26 | 28 | 15 |
| Anxiety/panic | 5961 (34) | 35 | 34 | 28 | 31 | 35 | 37 | 32 | 38 | 41 | 33 |
| Schizophrenia | 941 (5.4) | 6.1 | 4.5 | 4.7 | 4.5 | 5.4 | 4.2 | 2.0 | 4.4 | 3.8 | 9.1 |
| Laboratory results | |||||||||||
| Anemiac | 2541 (15) | 17 | 17 | 13 | 9 | 13 | 11 | 11 | 13 | 14 | 6 |
| Platelet count <100 k/μL | 2368 (14) | 11 | 26 | 1 | 11 | 14 | 21 | 22 | 26 | 7.6 | 9.1 |
| Creatinine >1.1 mg/dL | 3384 (20) | 22 | 21 | 22 | 18 | 17 | 12 | 8.2 | 12 | 23 | 17 |
| Bilirubin >1.1 g/dL | 294 (14) | 12 | 24 | 6 | 11 | 14 | 17 | 14 | 22 | 11 | 9 |
| Albumin <3.6 g/dL | 3564 (20) | 19 | 35 | 10 | 17 | 16 | 21 | 20 | 25 | 19 | 18 |
| INR >1.1 | 3653 (22) | 20 | 31 | 9.8 | 18 | 24 | 29 | 25 | 33 | 18 | 9.3 |
| FIB-4d score >3.25 | 5960 (36) | 31 | 55 | 12 | 34 | 35 | 49 | 53 | 58 | 26 | 21 |
INR, international normalized ratio; PTSD, post-traumatic stress disorder.
a
Data are n (%) except age, which is mean (SD).
b
Data are percentages, except age, which is mean (SD), and all patients, which is n (%).
c
Anemia is defined as a hemoglobin concentration <13 g/dL in men or <12 g/dL in women.
d
FIB-4 score29 = [age × aspartate aminotransferase] / [platelets × alanine aminotransferase1/2].